1-4 of 4
Stephen Fitter
Close
Sort by
Journal Articles

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

Kartini Asari, Susan L Heatley, PhD MD, Teresa Sadras, PhD, Tamara M Leclercq, PhD, Stephen Fitter, PhD, Chung Hoow Kok, PhD, Andrew C W Zannettino, PhD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, Deborah L White, PhD FFSc (RCPA)
Journal: Blood
Blood (2016) 128 (22): 3957.
https://doi.org/10.1182/blood.V128.22.3957.3957
Published: 2016
Journal Articles

Dysregulation of bone remodeling by imatinib mesylate

Kate Vandyke, Stephen Fitter, Andrea L. Dewar, Timothy P. Hughes, Andrew C. W. Zannettino
Journal: Blood
Blood (2010) 115 (4): 766–774.
https://doi.org/10.1182/blood-2009-08-237404
Published: 2010
Journal Articles

Dasatinib (Sprycel TM ) Inhibits Osteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism

Kate Vandyke, BSc Honours, Andrea Dewar, BSc, PhD, Peter Diamond, BSc, PhD, Stephen Fitter, BSc, PhD, Amanda N Farrugia, BSc Honours, Luen Bik To, MD, Timothy P. Hughes, MD, Andrew Christopher William Zannettino, BSc, PhD
Journal: Blood
Blood (2008) 112 (11): 3214.
https://doi.org/10.1182/blood.V112.11.3214.3214
Published: 2008
Journal Articles

Long-term imatinib therapy promotes bone formation in CML patients

Clinical Trials & Observations
Stephen Fitter, Andrea L. Dewar, Panagiota Kostakis, L. Bik To, Timothy P. Hughes, Marion M. Roberts, Kevin Lynch, Barrie Vernon-Roberts, Andrew C. W. Zannettino
Journal: Blood
Blood (2008) 111 (5): 2538–2547.
https://doi.org/10.1182/blood-2007-07-104281
Published: 2008
Includes: Supplemental data